We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Chemotherapy for Patients With Locally Advanced Pancreatic Cancer (LAPC) With Additional Chemo-radiotherapy (CRT) for Patients With Borderline Resectable Tumours

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2015 by Per Pfeiffer, Odense University Hospital.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01397019
First Posted: July 19, 2011
Last Update Posted: September 25, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Per Pfeiffer, Odense University Hospital
  Purpose
Treating patients with initial local non-resectable pancreatic cancer with a combination of oxaliplatin, irinotecan & 5-FU(FOLFIRINOX), consolidated with chemoradiotherapy in potentially resectable patients, will result in a high rate of tumor shrinkage allowing subsequent resection in patients with initial borderline resectable tumors and improved overall survival for all patients.

Condition Intervention Phase
Pancreatic Cancer Drug: Oxaliplatin, irinotecan, 5-FU & leucovorin Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Chemotherapy for Patients With Locally Advanced Pancreatic Cancer With Additional Chemo-radiotherapy for Patients With Borderline Resectable Tumours

Resource links provided by NLM:


Further study details as provided by Per Pfeiffer, Odense University Hospital:

Primary Outcome Measures:
  • 2 year survival rate [ Time Frame: 2 years ]

Estimated Enrollment: 50
Study Start Date: October 2011
Estimated Study Completion Date: January 2017
Estimated Primary Completion Date: January 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: FOLFIRINOX Drug: Oxaliplatin, irinotecan, 5-FU & leucovorin
FOLFIRINOX followed by 50 gy/27 F in combination with capecitabine in patients with borderline resectable tumors

Detailed Description:
Pancreatic cancer (PC) is the third most common gastrointestinal malignancy and one of the top ten leading causes of cancer deaths in the Western world. Patients with PC can be divided into three subgroups; resectable (rPC), locally advanced (LAPC) and metastatic (mPC). For patients with rPC surgery offers the best chance for long term survival. However it is estimated that only 20% of patients have rPC at the time of diagnosis. For patients with LACP, invasion of local large vessels is most often the cause for non-resectability. The median survival of these patients is between 6 to 12 months and long term survival in is extremely rare. The optimal treatment of LAPC is controversial. Treatment strategies vary between attempts to "downstage" the tumour to rPC, or treat the patients in a palliative setting only. Phase II studies and retrospective series have evaluated various treatments regimens and strategies including chemotherapy and radiotherapy (RT) alone or in combination - chemoradiotherapy (CRT). Results from these trials give no clear answer regarding the best treatment strategy. However, data from several studies shows that treatment of LAPC may result in shrinkage of the tumour, and thus potentially lead to a resection; also data suggests that CRT after chemotherapy improves treatment efficacy. Recent data from patients with mPC has show a combination of oxaliplatin, irinotecan and 5-FU (FOLFIRINOX) increases response rates from 10% to 30% and median survival to 11.1 months. The promising efficacy makes it natural to attempt this treatment in patients with LAPC.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria: (major)

  • non-metastatic pancreatic cancer
  • Performance status 0-1
  • Bilirubin < 1.5 UNL
  • Written informed consent

Exclusion Criteria: (major)

  • no prior abdominal radiotherapy
  • no prior chemotherapy for pancratic cancer
  • no severe comorbidity
  • patients must be able to undergo potential abdominal surgery
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01397019


Contacts
Contact: Jon K Bjerregaard, MD +45 65413834 jon.bjerregaard@ouh.regionsyddanmark.dk
Contact: Per Pfeiffer, Professor +45 6541 2921 per.pfeiffer@ouh.regionsyddanmark.dk

Locations
Denmark
Aalborg University Hospital Withdrawn
Aalborg, Denmark, 9100
Aarhus University Hospital Recruiting
Aarhus, Denmark, 8000
Contact: Morten Ladekarl, MD    +45 8949 2565      
Principal Investigator: Morten Ladekarl, MD         
Herlev University Hospital Recruiting
Herlev, Denmark, 2730
Contact: Benny V Jensen, MD    +45 3868 3868    bevi@heh.regionh.dk   
Principal Investigator: Benny V Jensen, MD         
Odense University Hospital Recruiting
Odense, Denmark, 5000
Contact: Jon K Bjerregaard, MD    +45 6541 3834    jon.bjerregaard@ouh.regionsyddanmark.dk   
Contact: Per Pfeiffer, Professor    +45 6541 2921    per.pfeiffer@ouh.regionsyddanmark.dk   
Principal Investigator: Per Pfeiffer, Professor         
Sub-Investigator: Jon K Bjerregaard, MD         
Sub-Investigator: Michael B Mortensen, MD         
Sponsors and Collaborators
Per Pfeiffer
Investigators
Principal Investigator: Per Pfeiffer, Professor Odense University Hospital
  More Information

Responsible Party: Per Pfeiffer, Professor, Odense University Hospital
ClinicalTrials.gov Identifier: NCT01397019     History of Changes
Other Study ID Numbers: DPSG 2010-01
First Submitted: July 18, 2011
First Posted: July 19, 2011
Last Update Posted: September 25, 2015
Last Verified: September 2015

Keywords provided by Per Pfeiffer, Odense University Hospital:
Pancreatic cancer
Chemotherapy
Chemoradiotherapy

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Oxaliplatin
Irinotecan
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action